Literature DB >> 17386267

PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.

John Brognard1, Emma Sierecki, Tianyan Gao, Alexandra C Newton.   

Abstract

Akt/protein kinase B controls cell growth, proliferation, and survival. We recently discovered a novel phosphatase PHLPP, for PH domain leucine-rich repeat protein phosphatase, which terminates Akt signaling by directly dephosphorylating and inactivating Akt. Here we describe a second family member, PHLPP2, which also inactivates Akt, inhibits cell-cycle progression, and promotes apoptosis. These phosphatases control the amplitude of Akt signaling: depletion of either isoform increases the magnitude of agonist-evoked Akt phosphorylation by almost two orders of magnitude. Although PHLPP1 and PHLPP2 both dephosphorylate the same residue (hydrophobic phosphorylation motif) on Akt, they differentially terminate Akt signaling by regulating distinct Akt isoforms. Knockdown studies reveal that PHLPP1 specifically modulates the phosphorylation of HDM2 and GSK-3alpha through Akt2, whereas PHLPP2 specifically modulates the phosphorylation of p27 through Akt3. Our data unveil a mechanism to selectively terminate Akt-signaling pathways through the differential inactivation of specific Akt isoforms by specific PHLPP isoforms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17386267     DOI: 10.1016/j.molcel.2007.02.017

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  294 in total

1.  Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.

Authors:  Noel A Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

2.  The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.

Authors:  Claudia Nitsche; Mouad Edderkaoui; Ryan M Moore; Guido Eibl; Noriyuki Kasahara; Janet Treger; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Gastroenterology       Date:  2011-10-29       Impact factor: 22.682

3.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

4.  Stress coping stimulates hippocampal neurogenesis in adult monkeys.

Authors:  David M Lyons; Paul S Buckmaster; Alex G Lee; Christine Wu; Rupshi Mitra; Lauren M Duffey; Christine L Buckmaster; Song Her; Paresh D Patel; Alan F Schatzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-30       Impact factor: 11.205

Review 5.  Distinct biological roles for the akt family in mammary tumor progression.

Authors:  Rachelle L Dillon; William J Muller
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 6.  Metabolic benefits of resistance training and fast glycolytic skeletal muscle.

Authors:  Nathan K LeBrasseur; Kenneth Walsh; Zoltan Arany
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-11-02       Impact factor: 4.310

7.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Authors:  Yanlin Yu; Meng Dai; Andrew Lu; Ellen Yu; Glenn Merlino
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

Review 8.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

9.  Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12.

Authors:  Urszula L McClurg; Nay C T H Chit; Mahsa Azizyan; Joanne Edwards; Arash Nabbi; Karl T Riabowol; Sirintra Nakjang; Stuart R McCracken; Craig N Robson
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

10.  The Akt1 isoform is required for optimal IFN-β transcription through direct phosphorylation of β-catenin.

Authors:  Benjamin N Gantner; Huali Jin; Feng Qian; Nissim Hay; Bin He; Richard D Ye
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.